[at Bloomberg] – Biogen Idec Inc., the maker of drugs for multiple sclerosis and hemophilia, agreed to pay as much as $320 million to develop medicines for blood disorders with Sangamo BioSciences Inc.
Read more on this.
Company Update: Biogen Idec Inc. (NASDAQ:BIIB) – Biogen to Develop Blood Medicines in Deal With Sangamo
January 09, 2014 at 07:00 AM EST
[at Bloomberg] – Biogen Idec Inc., the maker of drugs for multiple sclerosis and hemophilia, agreed to pay as much as $320 million to develop medicines for blood disorders with Sangamo BioSciences Inc. . . . → Read More: Company Update: Biogen Idec Inc. (NASDAQ:BIIB) – Biogen to Develop Blood Medicines in Deal With Sangamo
